Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)
Keyword(s):
Phase 2
◽
2017 ◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 705-705
2014 ◽
Vol 32
(15_suppl)
◽
pp. 519-519
◽